Eversheds Sutherland advises Edwards Lifesciences on its US$4.2bn sale of Critical Care
September 06, 2024
Eversheds Sutherland advises Edwards Lifesciences on its US$4.2bn sale of Critical CareSeptember 06, 2024 Eversheds Sutherland has advised Edwards Lifesciences on the US$4.2bn sale of its Critical Care product group to Becton, Dickinson and Company (BD). Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease. The Critical Care product group is an industry leader in advanced patient monitoring with advanced AI algorithms serving millions of patients globally. Key contacts
Lee Harris Partner United Kingdom Antony Walsh Partner United Kingdom Barri Mendelsohn Partner United Kingdom Rachel Cooper Partner United Kingdom Edward M. Tompkin-Haag Partner United Kingdom Kelly Holmes Partner United Kingdom Philip Crosbie Partner United Kingdom Christopher Murray Partner United Kingdom Latest Insights
Latest NewsLatest Eventslegal updates October 07, 2026 EU: Proposed KIDS Act Targets Online Child Safety guides and reports October 07, 2026 Technology, AI and the changing legal landscape of M&A guides and reports October 07, 2026 How AI is democratizing M&A for buyers and investors guides and reports October 07, 2026 Technology talent in M&A: retention, incentives and integration risk firm news October 07, 2026 Faster deals, deeper diligence: AI is transforming the legal landscape of M... firm news October 05, 2026 Leading finance partner joins Eversheds Sutherland firm news October 01, 2026 Eversheds Sutherland Switzerland appoints Dr. Michael Faske as new Partner client news September 21, 2026 |